Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation [Original Articles]

Conclusions—
Clinical phenotype and outcome of FG+ HCM was similar to G+ HCM but worse than G– HCM and FG+ HCM diagnosed in the context of family screening. These findings indicate the need for more intensive follow-up of FG+ and G+ HCM versus G– HCM and FG+ HCM in relatives.

Source: Circulation: Cardiovascular Genetics - August 9, 2017 Category: Cardiology Authors: van Velzen, H. G., Schinkel, A. F. L., Oldenburg, R. A., van Slegtenhorst, M. A., Frohn-Mulder, I. M. E., van der Velden, J., Michels, M. Tags: Clinical Studies, Genetics, Cardiomyopathy, Hypertrophy, Mortality/Survival Original Articles Source Type: research